(Total Views: 679)
Posted On: 03/05/2021 6:35:20 PM
Post# of 153998
The PR says the FDA wants further study in that severe subpopulation.
Really the same as CD10. Leronlimab shows a benefit for the sickest people in the study but they probably aren't a population size large enough to move the needle for regulatory confirmation.
Really the same as CD10. Leronlimab shows a benefit for the sickest people in the study but they probably aren't a population size large enough to move the needle for regulatory confirmation.
(0)
(3)
